RxDoctor Payments Data

Harmony Sierens, MD

Pediatric Rehabilitation Medicine · Grand Blanc, MINPI 1326201252

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,675 of the $5,828 with a category attached, or 63.1%. Ipsen Biopharmaceuticals, Inc accounts for 81.8% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $4,145, more than ten times the $359 reported in 2019.

$5,828in general payments, 2019–2025

Across 87 payments — averaging $66.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$5K
  • AbbVie$553
  • Averitas Pharma Inc.$170
  • Saol Therapeutics Inc.$153
  • Lilly USA, LLC$32
  • Azurity Pharmaceuticals, Inc.$31
  • plus $120 from 6 others
$201,209in research payments, 2019–2025

Across 115 payments — averaging $1749.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ipsen Pharma SAS$197K
  • Ipsen Innovation$4K

What the payments were for

  • Speaking & faculty fees$3,67563%
  • Food & beverage$2,15337%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric rehabilitation medicine providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$223,025
Medicare patients
174
Services billed
12,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl19$10,501
Gabapentin161$3,121
Pregabalin52$2,093
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen151$2,030
Baclofen90$1,692
Celecoxib13$1,506
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen53$950
Diazepam18$783
Oxycodone Hcl45$766
Morphine Sulfate ErMorphine Sulfate49$661
Methylphenidate Hcl12$440
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$432
Tizanidine Hcl40$363
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$308
Ibuprofen28$283

Paid to pharmacies, not to this prescriber.

Other pediatric rehabilitation medicine in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →